Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EVAMIST vs ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Evamist (estradiol transdermal spray) is a form of estrogen hormone replacement therapy. Estrogens diffuse into target cells and bind to estrogen receptors, which then translocate to the nucleus and regulate gene transcription, leading to estrogenic effects.
Acetaminophen: cyclooxygenase (COX) inhibitor, primarily central, analgesic and antipyretic. Aspirin: irreversible COX-1 and COX-2 inhibitor, analgesic, anti-inflammatory, antipyretic, antiplatelet. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.
Treatment of moderate to severe vasomotor symptoms due to menopause,Off-label: Prevention of postmenopausal osteoporosis (not FDA-approved for this indication)
Mild to moderate pain,Fever (acetaminophen and aspirin),Inflammatory conditions (aspirin)
1.53 mg per actuation (as estradiol hemihydrate); 1 spray to the inner forearm once daily.
1-2 tablets (each containing acetaminophen 300 mg, aspirin 300 mg, codeine phosphate 30 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets/day.
Terminal elimination half-life is 4 hours; clinical context: dosing every 6-8 hours maintains therapeutic levels
Acetaminophen: 2-3 hours (terminal). Aspirin: 15-30 minutes (parent drug); salicylate: 2-3 hours at low doses, 15-30 hours at high doses due to saturable metabolism. Codeine: 2.5-4 hours. Clinical context: Prolonged half-life of salicylate at high doses increases risk of toxicity; hepatic impairment prolongs acetaminophen and codeine half-lives.
Estradiol is primarily metabolized in the liver via CYP3A4 and other cytochrome P450 enzymes. It is also metabolized in the gastrointestinal tract and skin. Major metabolites include estrone and estriol, which are conjugated (sulfates and glucuronides) and excreted in urine.
Acetaminophen: hepatic via CYP2E1, CYP1A2, CYP3A4; glucuronidation and sulfation; NAPQI formation. Aspirin: hepatic hydrolysis to salicylate; conjugation with glycine and glucuronic acid. Codeine: hepatic via CYP2D6 to morphine (active); also via CYP3A4 to norcodeine.
Renal (90%) as metabolites; fecal (<5%); biliary (<1%)
Acetaminophen: renal excretion of metabolites (glucuronide and sulfate conjugates, ~85-90%), minor parent drug (<5%). Aspirin: renal excretion of salicylate and its metabolites (salicyluric acid, glucuronides, gentisic acid), dose-dependent; at therapeutic doses, ~50-80% as free salicylate and conjugates. Codeine: renal excretion of free and conjugated codeine (about 90%) and metabolites (morphine, norcodeine).
80% bound to albumin and alpha-1-acid glycoprotein
Acetaminophen: 10-25% (albumin). Aspirin: 50-80% (albumin), dose-dependent; salicylate: 75-90% (albumin). Codeine: ~7% (albumin).
3-5 L/kg; indicates extensive tissue distribution
Acetaminophen: 0.9-1.0 L/kg (large distribution including liver). Aspirin: 0.15-0.2 L/kg (low Vd, confined to plasma and extracellular fluid); salicylate: 0.2-0.3 L/kg. Codeine: 3-6 L/kg (extensive tissue distribution). Clinical meaning: Large Vd for codeine suggests extensive tissue binding; aspirin Vd is small, consistent with limited extravascular distribution.
Intranasal: 70%; oral: not applicable (first-pass metabolism)
Oral: Acetaminophen: 85-95%. Aspirin: 40-60% (due to first-pass hydrolysis to salicylate). Codeine: ~50% due to first-pass metabolism.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min); use with caution.
GFR 30-59 m L/min: Administer every 6 hours; maximum 6 tablets/day. GFR 15-29 m L/min: Administer every 12 hours; maximum 4 tablets/day. GFR <15 m L/min: Not recommended due to accumulation of codeine metabolites.
Contraindicated in Child-Pugh Class B and C (moderate to severe hepatic impairment). No data for mild impairment; use with caution.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50% and extend interval to every 6 hours; maximum 4 tablets/day. Child-Pugh Class C: Contraindicated.
Not indicated for use in pediatric patients. Safety and efficacy not established.
Not recommended for children <12 years due to aspirin risk of Reye syndrome. For children ≥12 years: Dose based on codeine component (0.5-1 mg/kg/dose) with maximum acetaminophen 75 mg/kg/day and aspirin 100 mg/kg/day. Typical: 1 tablet (acetaminophen 300 mg/aspirin 300 mg/codeine 30 mg) every 4-6 hours as needed; max 4 tablets/day.
No specific dose adjustment recommended; however, initiate at lowest effective dose due to increased risk of adverse effects (e.g., thromboembolism, malignancy) in elderly.
Start with lowest effective dose (e.g., 1 tablet every 6 hours); monitor renal and hepatic function; maximum 6 tablets/day due to increased sensitivity and risk of adverse effects.
Estrogen therapy increases the risk of endometrial cancer in women with an intact uterus. Use of unopposed estrogens is associated with an increased risk of endometrial hyperplasia and carcinoma. Additionally, estrogens should not be used to prevent cardiovascular disease or dementia. The Women's Health Initiative (WHI) study reported increased risks of stroke, deep vein thrombosis, pulmonary embolism, and breast cancer with estrogen-alone therapy.
Risk of medication errors: confusion between different strengths and concentrations of acetaminophen can result in accidental overdose and fatal hepatotoxicity. Aspirin use in children and teenagers with viral infections is associated with Reye's syndrome.
Risk of endometrial cancer: Use progestin in women with intact uterus.,Cardiovascular disorders: Increased risk of stroke, DVT, pulmonary embolism, especially in smokers and older women.,Breast cancer: Increased risk with long-term use.,Dementia: Increased risk in women ≥65 years old.,Gallbladder disease.,Hypercalcemia in patients with breast cancer and bone metastases.,Retinal vascular thrombosis: Discontinue if sudden vision loss occurs.,Fluid retention: Use with caution in patients with conditions exacerbated by edema.,Hypothyroidism: May need increased thyroid replacement dose.,Hepatic impairment: Contraindicated in severe liver disease.
Hepatotoxicity (acetaminophen dose >4 g/day), Reye's syndrome (aspirin in children), respiratory depression (codeine), tolerance/dependence, bleeding risk (aspirin), GI toxicity, renal impairment, hypersensitivity reactions.
Undiagnosed abnormal genital bleeding,Known, suspected, or history of breast cancer,Known or suspected estrogen-sensitive neoplasia,Active or history of deep vein thrombosis or pulmonary embolism,Active or history of arterial thromboembolic disease (e.g., stroke, MI),Known thrombophilic disorders (e.g., Protein C, S, or antithrombin deficiency),Hepatic impairment or disease,Pregnancy,Hypersensitivity to estradiol or any ingredient
Hypersensitivity to any component, active peptic ulcer disease, bleeding disorders, severe hepatic impairment, severe respiratory depression, children with viral illness (aspirin), pregnancy (third trimester for aspirin, codeine cautious).
Grapefruit and grapefruit juice may increase estradiol levels; avoid excessive consumption. No other significant food interactions reported.
Avoid alcohol due to increased risk of acetaminophen hepatotoxicity and aspirin-induced GI bleeding. Avoid large amounts of caffeine or high-tyramine foods (e.g., aged cheeses, cured meats) as they may affect CYP2D6 metabolism of codeine.
Evamist (estradiol transdermal spray) is contraindicated in pregnancy. First trimester exposure is associated with congenital anomalies including cardiovascular and limb defects. Second and third trimester exposure increases risk of urogenital abnormalities and potential long-term reproductive tract effects in offspring. Use is not recommended at any gestational stage.
Acetaminophen: Generally considered low risk; association with ASD and ADHD with prolonged use not fully established. Aspirin: First trimester: possible increased risk of gastroschisis; second trimester: relatively safe; third trimester: risk of premature closure of ductus arteriosus, oligohydramnios, and increased peripartum hemorrhage. Codeine: First trimester: possible neural tube defects; second and third trimesters: risk of respiratory depression, withdrawal in neonate with chronic use; neonatal opioid withdrawal syndrome (NOWS) possible.
Estradiol is excreted in breast milk. The milk-to-plasma ratio is approximately 0.1-0.2. Studies show low concentrations in milk, but long-term effects on the infant are unknown. Evamist is not recommended during breastfeeding due to potential hormonal disruption and reduced milk production.
Acetaminophen: M/P ratio approximately 0.91-1.42; considered safe. Aspirin: M/P ratio 0.08-0.15; high doses may cause Reye's syndrome; avoid or use low doses. Codeine: M/P ratio about 2.5; variable metabolism; risk of CNS depression in infant; avoid due to potential for toxicity in CYP2D6 ultrarapid metabolizers.
No dosing adjustments applicable as Evamist is contraindicated in pregnancy. In the non-pregnant state, no dosage adjustment is needed. Pharmacokinetic changes during pregnancy (increased clearance, volume of distribution) are not relevant as the drug should not be used.
Acetaminophen: No dose adjustment needed. Aspirin: Avoid in third trimester; use lowest effective dose if necessary. Codeine: Avoid in pregnancy; if used, lowest effective dose for shortest duration; caution for CYP2D6 polymorphism. Pharmacokinetic changes: Increased clearance of codeine during pregnancy may require higher doses but risk outweighs benefit.
Apply EVAMIST to clean, dry, intact skin of the axilla or inner thigh. Avoid application to irritated or broken skin. Rotate application sites to minimize local skin reactions. Do not apply to the breast or vaginal area. For optimal absorption, wait at least 1 hour after application before showering or swimming. Monitor serum estradiol levels if inadequate symptom relief or adverse effects occur.
Combination analgesic with acetaminophen (hepatotoxic at high doses), aspirin (antiplatelet, GI irritant, contraindicated in children <12 due to Reye's syndrome), and codeine (prodrug to morphine via CYP2D6; efficacy depends on CYP2D6 phenotype; risk of CNS/respiratory depression). Avoid in severe hepatic/renal impairment, active peptic ulcer, bleeding disorders, or concomitant use of other CNS depressants. Maximum acetaminophen dose from all sources: 4 g/day.
Apply the gel to clean, dry skin on your armpit or inner thigh.,Rotate application sites daily to avoid skin irritation.,Avoid applying to the breast or vaginal area.,Do not wash the application area for at least 1 hour after applying.,Keep away from children and pets; wash hands thoroughly after application.,Do not use if you are pregnant, breastfeeding, or have a history of certain cancers.,Report any unusual vaginal bleeding, breast lumps, or signs of blood clots immediately.
Do not exceed recommended dose; acetaminophen overdosage can cause serious liver damage.,Do not take with other products containing acetaminophen or aspirin.,Avoid alcohol while taking this medication to reduce risk of liver toxicity and GI bleeding.,This product contains aspirin; do not give to children/teenagers with chickenpox or flu-like symptoms to avoid Reye's syndrome.,May cause drowsiness; do not drive or operate machinery until you know how you react.,Codeine is a narcotic pain reliever with abuse potential; use exactly as prescribed.,Seek medical attention if you experience signs of allergic reaction (rash, difficulty breathing) or bleeding (black/tarry stools, unusual bruising).
No interactions on record
"Pirenzepine, a selective M1 muscarinic antagonist, reduces gastrointestinal motility and secretions, while codeine, an opioid agonist, also decreases gastrointestinal motility via mu-opioid receptors. Concurrent use leads to additive anticholinergic and opioid effects, resulting in enhanced risk of severe constipation, paralytic ileus, and central nervous system depression. Clinically, patients may experience exacerbated sedation, respiratory depression, and urinary retention."
"Ropinirole, a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome, may reduce the analgesic efficacy of codeine. This is likely due to pharmacodynamic antagonism at central dopamine and opioid receptors, as well as potential pharmacokinetic interactions that decrease the conversion of codeine to its active metabolite morphine via CYP2D6 inhibition by ropinirole. The resultant blunted opioid response can lead to inadequate pain control, necessitating dose adjustment or alternative therapy."
"Vemurafenib induces CYP3A4, significantly reducing the plasma concentrations of codeine, which is metabolized via CYP3A4 to its active metabolite morphine. This may diminish codeine's analgesic efficacy, potentially leading to inadequate pain control. Additionally, reduced formation of morphine may lower the risk of opioid-related adverse effects."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EVAMIST vs ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE, answered by our medical review team.
EVAMIST is a Estrogen Replacement that works by Evamist (estradiol transdermal spray) is a form of estrogen hormone replacement therapy. Estrogens diffuse into target cells and bind to estrogen receptors, which then translocate to the nucleus and regulate gene transcription, leading to estrogenic effects.. ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE is a Opioid Agonist that works by Acetaminophen: cyclooxygenase (COX) inhibitor, primarily central, analgesic and antipyretic. Aspirin: irreversible COX-1 and COX-2 inhibitor, analgesic, anti-inflammatory, antipyretic, antiplatelet. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EVAMIST and ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EVAMIST is: 1.53 mg per actuation (as estradiol hemihydrate); 1 spray to the inner forearm once daily.. The standard adult dose of ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE is: 1-2 tablets (each containing acetaminophen 300 mg, aspirin 300 mg, codeine phosphate 30 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EVAMIST and ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EVAMIST is classified as Category C. Evamist (estradiol transdermal spray) is contraindicated in pregnancy. First trimester exposure is associated with congenital anomalies including cardiovascular and limb defects. S. ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE is classified as Category D/X. Acetaminophen: Generally considered low risk; association with ASD and ADHD with prolonged use not fully established. Aspirin: First trimester: possible increased risk of gastrosch. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.